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1. Introduction
Neuropathic pain (NeuP) is defined as pain that arises as a ‘direct 
consequence of a lesion or disease affecting the somatosensory 
system’.1 Importantly, NeuP differs from nociceptive pain in respect 
of causes, mechanisms, symptomatology and different therapeutic 
approaches required for successful management. 
The burden of NeuP for the patient is substantial. NeuP is associated 
with psychological distress, physical disability and reduced overall 
quality of life.2-5 A systematic review and meta-analysis by Doth et 
al.6 showed lower health-utility scores in patients with NeuP than the 
general population and in people with other chronic conditions like 
Parkinson’s disease, heart failure, motor neurone disease, cancer, and 
stroke. Patients with peripheral NeuP are generally affected by difficulty 
in sleeping, lack of energy, drowsiness, and difficulty in concentrating.7 
The problem is further compounded by the fact that globally, and 
in South Africa, NeuP is often underdiagnosed and inappropriately 
treated, exacerbating the burden of this already debilitating condition.
The costs of NeuP are considerable,3,8 with misdiagnosis, 
mistreatment, and mental and physical comorbidities such as 
depression and nerve damage contributing to the cost, in addition 
to usual diagnostic and treatment costs. Indeed, it has been reported 
that patients with NeuP have annual healthcare costs threefold higher 
than the costs for matched control populations.9 
Reduced work ability of patients and carers, and medical expenses 
also contribute to the overall cost of NeuP.10 A survey in the 
USA revealed that almost 65% of working patients with painful 
diabetic neuropathy reported absence from work or decreased 
work productivity due to pain.11 Another study reported that the 
employment status was reduced, owing to pain, in 52% of patients 
with peripheral NeuP.7 
In South Africa there are a number of specific challenges to 
evaluating and treating NeuP. Lack of education and awareness 
among physicians, including specialists, was noted as a problem 
in South Africa, leading to suboptimal identification, assessment 
and management of NeuP. For example, inappropriate use of non-
steroidal anti-inflammatory drugs (NSAIDs) and opioids as first-line 
treatment is widespread, and inappropriate back surgery is common. 
Referrals to pain clinicians often come too late, and even in specialist 
centres a multidisciplinary approach is not always taken. 
Patient access to care varies widely in South Africa, from rural to urban 
areas and across socioeconomic divides. But access to care does not 
guarantee access to the most appropriate drugs, as financial and supply-
chain constraints, and restricted formulary in the public sector and 
restricted reimbursement in the private sector limit access to appropriate 
medications.12 Along with access issues, lack of trained personnel is also a 
problem.13,14 Added to these challenges, which are not necessarily unique 
to South Africa, is the high rate of HIV in this country and the paucity of 
evidence for treating painful HIV-related neuropathy.15
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To improve NeuP management in South Africa, regional guidelines 
for NeuP management, which take local settings into account, are 
vital. The consensus recommendations described here aim to help 
healthcare practitioners in South Africa become more aware of NeuP, 
better skilled at its diagnosis, and equipped to select appropriate 
treatment options for patients suffering from NeuP.
2. Methods
2.1 Expert panel
A panel with special expertise in diagnosis and management of NeuP 
met in Johannesburg, South Africa on 9 July 2011. The panel included 
specialists from the fields of psychiatry, neurology, neurosurgery, 
anaesthesiology, family medicine and basic science.
The panel collaborated with a French NeuP specialist to critically 
analyse available randomised controlled trials (RCTs) and evidence-
based international and regional guidelines for the evaluation and 
treatment of NeuP. The objective of the meeting was to develop 
clear clinical practice guidelines to aid the diagnosis and medical 
management of NeuP in South Africa.
2.2 Evidence evaluation
Recommendations from recent international and regional guidelines 
were reviewed in addition to discussion of recent systematic reviews, 
meta-analyses, and peer-reviewed randomised, double-blind, 
placebo-controlled studies;15-30 a number of Cochrane reviews were 
also referred to.31-40 The validity, clinical relevance, and applicability 
of the evidence for peripheral and central NeuP in South Africa were 
discussed. 
The main sources of evidence were the 2010 guidelines from 
the European Federation of Neurological Societies (EFNS)26 and 
recommendations from both the Neuropathic Pain Special Interest 
Group of the International Association for the Study of Pain 
(IASP)27,41 and the French Pain Society,16 all based on systematic 
reviews of available evidence. A systematic review of evidence 
by Danish pain experts,17 consensus recommendations from the 
Canadian Pain Society19 and consensus recommendations from 
experts in Latin America,18 the Middle-East region (MER)21 and 
the Maghreb region22 were also consulted. Reference was also made 
to the American Academy of Neurology (AAN) guidelines for 
management of painful diabetic peripheral neuropathy (DPN);20 
postherpetic neuralgia (PHN)24 and trigeminal neuralgia (TN)23 
were also referred to. 
It was decided against using number-needed-to-treat (NNT) as 
the sole measure of efficacy in making recommendations for South 
Africa, since NNT does not provide a complete picture of the quality 
of a study, particularly as the studies assessed vary widely in number 
of participants and quality of study design. 
After considering the evidence, the panel achieved consensus on 
a number of recommendations that are supported by best scientific 
evidence. The recommendations include some agents that may not be 
indicated for use in NeuP. Similarly, some agents that are supported 
by best scientific evidence are not available in South Africa (e.g. 
the topical lidocaine patch), so are mentioned here but have been 
excluded from the final recommendations.
The levels of evidence stated in this review follow the levels 
attributed in the formal systematic reviews from which the data were 
sourced (refer to Appendix A). 
2.3 Guideline development
The discussions and consensus statements were recorded at the 
meeting and written up as a full manuscript draft by a professional 
medical writer. The panel reviewed, edited, and provided comments 
on the outline and drafts of the manuscript until a final version was 
reached that was approved by all members.  
3. Results
3.1 Epidemiology and burden of NeuP
Estimating the prevalence of NeuP is notoriously difficult – a recent 
systematic review by Smith and Torrence42 found that estimates vary 
widely, confounded by underreporting and inconsistent definitions and 
diagnostic criteria. They suggest a prevalence of 6 - 8% in the general 
population. They estimate that approximately 20% of patients with 
diabetes and 8% of people who have had herpes zoster suffer from NeuP. 
There are no published estimates of NeuP prevalence in South Africa. 
The prevalence of NeuP resulting from common aetiologies (see Table 
1) is likely to be similar to other countries, but with a large additional 
component resulting from the high rate of HIV in this country. 
Low back pain is a major contributor to NeuP prevalence globally, 
and there may be a neuropathic component in nearly 50% of black 
Africans with lower back pain.43 A similar rate of neuropathic pain 
(55%) was reported in adults with lower back pain in an outpatient 
setting in the Arabian Gulf region.44 PHN and DPN are also leading 
causes of NeuP, but data on the prevalence of these causes in South 
Africa are limited. The International Diabetes Federation (IDF) 
Diabetes Atlas estimates the prevalence of type II diabetes in the 
Africa region in 2010 to be 3.8%,45 which is below the global average 
but expected to rise disproportionately in the developing world in the 
coming decades.46 In diabetes patients attending outpatient clinics in 
the Middle East, 54% met the criteria for painful DPN.47 The reported 
occurrence of peripheral neuropathy in patients with diabetes varies 
widely in sub-Saharan African countries, from 4% in Zimbabwe to 
69% in Nigeria,48 and was estimated at 28% among black African 
diabetes patients in a 1997 audit of public-sector diabetes care in 
South Africa.49 While not all diabetes-related neuropathy is painful, 
as many as 20% of diabetes patients could suffer from NeuP related 
to DPN,42 and this clearly represents a large, and growing, cause of 
NeuP, in South Africa.
According to the 2010 global report by the United Nations 
Program on HIV/AIDS (UNAIDS), 5.6 million people in South 
Africa are living with HIV.50 HIV-associated sensory neuropathy 
(HIV-SN), a frequent complication of both HIV and neurotoxic 
antiretroviral medications such as stavudine, is therefore a major 
concern in South Africa. 
Prevalence of NeuP was reported to be 20.9% among South 
African AIDS patients who had not received prior antiretroviral 
treatment.51 The prevalence of symptomatic HIV-SN was 57% in 395 
HIV-positive black South Africans exposed to stavudine, with 76% of 
affected individuals experiencing pain as their primary symptom.52 In 
598 HIV-infected individuals in South Africa, the frequency of HIV-
SN was 37% in individuals never exposed to antiretroviral drugs, 
increasing to 60% in individuals receiving antiretroviral therapy. 
In both groups of patients, the neuropathy was symptomatic in 
approximately 60% of individuals, with almost all these individuals 
reporting pain and/or paraesthesias.53
A recent study conducted in a South African hospital revealed that 
although 71% of the patients with HIV/AIDS had pain documented 
in their medical charts, only 34% of the patients reported adequate 
pain management.54 HIV-positive outpatients are no better off, with 
over 40% of ambulatory patients in pain not receiving any treatment, 
and of those patients who received treatment, less than 3% received 
drugs recommended for the treatment of NeuP, despite over a third 
of the patients having symptoms consistent with HIV-SN.55 These 
studies highlight that the neuropathic component of HIV-related 
pain is probably poorly recognised and undertreated in South Africa.
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3.2 Pathophysiology of NeuP
NeuP, by definition, arises as a ‘direct consequence of a lesion or disease 
affecting the somatosensory system’.1 While the detailed mechanisms 
that underlie NeuP are not fully understood, they are thought to 
operate at both central and peripheral levels (Fig. 1): (A) at the level 
of peripheral nerves, there is sensitisation, ectopic transmission and 
spontaneous discharges; (B) changes in central modulatory systems, 
predominantly in spinal neurones, lead to central sensitisation. 
The relationship between these mechanisms and the resulting 
symptoms is not straightforward – one mechanism may give rise to 
more than one symptom and one individual symptom may result 
from multiple mechanisms.56
Knowledge of the possible mechanisms underlying NeuP is helpful 
in understanding and improving treatment of NeuP. An overview of 
the basic mechanisms and targets for disease is given in Fig. 1. 
3.3 Aetiology of NeuP
Currently there is no universally accepted classification for NeuP 
types. However, four broad classes of diseases are recognised based 
on aetiology and anatomy (Table 1).
3.4 Clinical features of NeuP
Patients with NeuP experience symptoms arising in an area of altered 
sensation (numbness/loss of sensation and/or hyperexcitability) and 
exhibit a number of typical observable signs.57 
The painful symptoms include both spontaneous pain (i.e. 
occurs with no apparent stimulation), which can be continuous 
or paroxysmal, and evoked pain. Terms commonly used to 
describe painful and unpleasant sensations (dysaesthesias) 
include burning, shooting, and electric shock-like pain. A 
number of altered, but not unpleasant, sensations (paraesthesias) 
– tingling, ants crawling, and pins and needles – are also 
common. Stimulus-evoked pain is described as allodynia if 
normally non-painful stimuli (e.g. light breeze, skin contact with 
clothing, temperature change) evoke pain, and as hyperalgesia 
when a normally painful stimulus (e.g. pinprick) evokes a 
heightened pain sensation.58
3.5 Diagnosis and evaluation of NeuP
NeuP is distinct from other chronic pain types that have an intact 
nociceptive system (nociceptive pain). For the differential diagnosis 
Fig. 1. Lesion of peripheral nerves results in peripheral sensitisation (A), via 
a number of mechanisms. For example, increased expression of sodium and 
calcium channels, in unmyelinated (C-fibre) and thinly myelinated (Aδ-
fibre) primary afferent neurones can lead to spontaneous discharges, reduced 
thresholds for activation, enhanced responses to stimuli and abnormal neu-
ronal sprouting (e.g. neuroma formation). This peripheral sensitisation can 
drive dramatic secondary changes in the spinal cord dorsal horn, leading to 
central sensitisation (B) – an increase in the general excitability of multire-
ceptive spinal cord neurones. The glutamate NMDA receptor plays a central 
role in these changes, which are manifested by increased neuronal activity in 
response to noxious stimuli, expansion of neuronal receptive fields and spread 
of spinal hyperexcitability to other segments. Dorsal horn neurones receive a 
powerful descending modulatory control from the brain and brainstem, and 
dysfunction of the descending inhibitory serotonergic and noradrenergic path-
ways may contribute to central sensitisation. Each of these malfunctioning sys-
tems represents a target for drugs used to treat NeuP: 1. carbamazepine and 
lidocaine target sodium channel; 2. gabapentin and pregabalin target calcium 
channels (the α2δ subunit) on terminals in spinal neuronal circuits; and 3. 
serotonin/noradrenaline reuptake inhibitors (SNRIs) and tricyclic antidepres-
sants (TCAs) target descending serotonergic and noradrenergic pathways.
Table 1. Aetiology-based classification of painful peripheral neuropathies
Focal or multifocal lesions of the 
peripheral nervous system
Generalised lesions of the 
peripheral nervous system 
(polyneuropathies) Lesions of the CNS
Complex neuropathic 
disorders
Common/important
Post-traumatic neuralgia
Phantom limb and stump pain
PHN
Diabetes mellitus (leading to DPN)
Alcohol
HIV (leading to HIV-SN) 
Antiretroviral agents
Chemotherapy
SCI
Stroke
Complex regional pain 
syndromes types I 
(controversial) and II 
Others/miscellaneous
Diabetic proximal 
mononeuropathy
Entrapment syndromes
Ischaemic neuropathy
Heavy metals, e.g. thallium, arsenic
Drugs, e.g. metronidazole, isoniazid, 
vinca alkaloids
Metabolic/genetic, e.g. amyloid, 
uraemia, Fabry disease
Nutritional, e.g. vitamin B 
deficiencies
MS
Syringomyelia
Spinal infarction
Modified from Baron et al.56 CNS – central nervous system, PHN - postherpetic neuralgia, DPN - diabetic peripheral neuropathy, HIV-SN - HIV-associated sensory neuropathy; SCI - spinal 
cord injury; MS - multiple sclerosis.
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of NeuP it is helpful to analyse the exact quality of somatosensory 
abnormalities in the affected area as well in the areas adjacent to the 
sensory deficit.56 Clinical tools, such as questionnaires for screening 
and assessment, focus on the presence and quality of neuropathic 
pain, and can be used to alert a clinician to the likelihood of NeuP 
and the need for a careful examination. It is important to note 
that screening tools fail to identify about 10 - 20% of patients with 
clinician-diagnosed NeuP,59 and they should be used as a guide for 
further diagnostic evaluation and pain management but cannot 
replace clinical judgment.
3.5.1 Screening tools 
In recent years, several standardised screening tools have been 
developed to aid the identification and classification of NeuP on 
the basis of patient-reported verbal descriptors of pain qualities.59 
These include (among others) painDetect, ID-Pain, Leeds Assessment 
of Neuropathic Symptoms and Signs (LANSS), Neuropathic Pain 
Questionnaire (NPQ) and Douleur Neuropathique en 4 questions (DN4). 
Most of these questionnaires include questions about burning pain, 
paraesthesias, pain attacks, mechanical and thermal hypersensitivity, 
and numbness.60,61 They are attractive because of their ease of use by 
both professionals and patients, in clinic or via telephone or Internet, 
and because they provide immediate information.61 
The painDetect questionnaire was developed and validated in 
Germany to identify NeuP components in back pain, whereas 
ID-Pain, DN4 and LANSS were developed to help differentiate 
nociceptive pain and NeuP.62,63 
The DN4 scale is based on the patient’s description, and physician 
examination, of sensory dysfunction – it has a sensitivity of 82.9% 
and specificity of 89.9%.64 The 10-item questionnaire includes 7 items 
related to symptoms and 3 related to clinical examination. A total 
score of 4 or higher suggests NeuP. The 7 sensory descriptors can 
be used as a self-report questionnaire with similar results. The DN4 
has validated translations in 15 languages (in addition to its original 
French), and while it is not validated in South African languages, the 
DN4 questionnaire (Fig. 2) is recommended as it is short, quick and 
easy to follow in regular clinical practice. 
3.5.2 Clinical assessment 
A simple examination-based way to identify NeuP and differentiate from 
nociceptive pain is the ‘3L’ approach: Listen, Locate and Look (Table 2).65
Listen to the verbal description of pain and any non-painful 
symptoms in the same area as the pain. 
Locate the region of pain and document with a pain drawing, 
created either by the patient or by the physician. Any abnormal 
sensations may also be highlighted on the same illustration. 
Look for sensory abnormalities and recognise the distribution 
pattern. A careful inspection of the painful body area should be 
carried out and any differences in colour, texture, temperature, etc. 
should be noted. A simple bedside examination of somatosensory 
functions is recommended, including touch, cold, warmth and pain 
sensibility (Table 3).59 The aim is to identify altered sensation in the 
painful area, and hence responses should be compared with a non-
painful adjacent area. 
Physicians need to consider a holistic approach to diagnose and 
treat the underlying condition and comorbid conditions. This will 
lead to improvement of patients’ overall quality of life, physical 
functioning and sleep quality, along with a reduction of the 
psychological distress associated with NeuP conditions. Where the 
underlying pathology is understood, it is recommended that both 
symptomatic treatment (pain management) and treatment of the 
aetiology should be initiated. Where the underlying pathology is 
not clear, symptomatic treatment should be initiated while further 
testing is done to clarify the pathology.
3.5.3 Recommendations
•	 Apply screening tools and careful clinical examination and 
screening tools to help identify and evaluate NeuP. 
•	 Use simple screening tools such as DN4 to help identify likely NeuP.
•	 Employ the 3L approach to differentiate NeuP from nociceptive 
pain: listen to the verbal description of pain, locate the region of 
pain and look for somatosensory deficits with the help of simple 
bedside tests. 
3.6 Pharmacological treatments
Despite a reported 66% increase in published randomised, placebo-
controlled trials (RCTs) for NeuP in the past 5 years,17 there are 
several gaps in the evidence for NeuP treatments. Although many 
types of peripheral and central NeuP occur in clinical practice, 
most RCTs have included patients with either PHN or painful DPN. 
Importantly, there are very few head-to-head trials comparing 
different treatments, making direct comparisons of efficacy and 
tolerability difficult or impossible. HIV neuropathy and chronic 
radiculopathy seem less responsive to drugs generally found useful 
in other NeuP conditions based on large-scale trials, particularly 
tricyclic antidepressants (TCAs), pregabalin, and gabapentin.15,66 
Central NeuP is also difficult to treat, and while it appears to 
respond to the same drug treatments as peripheral NeuP, the 
response is generally less robust.66 
3.6.1 Treatment recommendations by international guidelines 
In the past few years, several national, regional and international 
guidelines, systematic reviews and expert panel recommendations 
have been published for the treatment of NeuP,16-19,21,22,26,27,41 and for 
specific aetiologies;20,23,24 these are summarised in Table 4a and 4b.
The first-line treatments recommended by most of the guidelines 
are TCAs, α2δ-ligands or gabapentinoids (pregabalin and gabapentin), 
and topical lidocaine (for localised NeuP), with selective serotonin/
noradrenaline reuptake inhibitors (SNRIs) sometimes included as 
first-line, sometimes second-line therapy. All guidelines recommend 
reserving tramadol and stronger opioid analgesics for second- or 
third-line treatment (Table 4a).
The EFNS26 and the French16 publications provide recomm- 
endations separately for specific NeuP aetiologies, while the others 
make general recommendations for peripheral (and central) NeuP. 
3.6.2 Treatment framework 
The initial approach to treatment of NeuP should include a 
thorough investigation and treatment of underlying pathology. The 
treatment choice should address the possible pain mechanisms 
as well as comorbid conditions (anxiety, depression, sleep 
disorders) associated with pain. Other considerations for treatment 
selection include potential for adverse effects, drug interactions, 
contraindications, risks of misuse and abuse, patients’ response to 
prior therapy, and cost. Patient education is a vital aspect of NeuP 
management. It is important to clearly explain the mechanisms of 
NeuP as well as the goals of treatment to the patient in order to 
maximise treatment benefits and manage treatment expectations. 
The patient should be informed that the onset of analgesic effect 
will take time and reduction of pain is not achieved quickly, in most 
cases. Non-pharmacological methods of coping with pain should be 
discussed, including the importance of stress reduction and good 
sleep hygiene, and access to physical therapy and psychotherapy 
should be recommended or arranged. 
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3.6.3 Peripheral NeuP 
Four classes of drugs have good evidence of efficacy in the treatment 
of non-localised NeuP: α2δ-ligands (pregabalin and gabapentin), 
TCAs (low-dose amitriptyline or other TCA), SNRIs (duloxetine 
and venlafaxine), and opioids (tramadol, methadone and morphine). 
The efficacy and safety of these agents are briefly discussed below 
and also summarised in Table 5.
3.6.3.1 α2δ-ligands (pregabalin and gabapentin)
Pregabalin and gabapentin are recommended (grade A) as first-line therapy 
Fig. 2. DN4 questionnaire.
DN4 Questionnaire
PATIENT INTERVIEW
Question 1. Does the pain have any of the following characteristics?
1. Burning
2. Painful sensation of cold
3. Electric shocks
Question 2. Is the pain associated with any of the following symptoms in the same area?
4. Tingling
5. Pins and needles
6. Numbness
7. Itching
PATIENT EXAMINATION
Question 3. Is the pain located in an area where the physical examination may reveal one 
or more of the following characteristics?
8. Hypoaesthesia to touch
9. Hypoaesthesia to prick
Question 4. In the painful area, can the pain be caused or increased by:
10. Brushing
YES = 1 point
NO = 0 points
Patient’s score: _____/10
If the patient’s score is ≥4, the test is positive. (sensitivity 82.9%; specificity 89.9%)
Reprinted from Bouhassira D, et al.64 This questionnaire has been reproduced with permission of the International Association for the Study 
of Pain® (IASP®). The questionnaire may not be reproduced for any other purpose without permission.
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by IASP, EFNS, and French guidelines, based on high-quality evidence of 
efficacy established in multiple RCTs.16,26,27 The AAN guidelines for painful 
DPN recommend pregabalin (level A) because of the availability of strong 
evidence and gabapentin (level B evidence).20 A systematic review by 
Danish pain experts17 and several Cochrane reviews32,35,67 confirm the 
efficacy of these α2δ-ligands for the treatment of NeuP. 
Although pregabalin and gabapentin appear to have similar efficacy, 
there are minor differences in the pharmacokinetic profile of these two 
drugs.27 Gabapentin pharmacokinetics are nonlinear (due to saturable 
absorption), and dosing requires careful titration. Treatment should be 
initiated at low dosages with gradual increases until pain relief, dose-
limiting adverse effects, or a dose of 3 600 mg/day in 3 divided doses 
is/are reached. Pregabalin has linear pharmacokinetics and dosing is 
more straightforward. Dosing can start at 25 mg/day (at night), and 
be titrated slowly up to a maximum dose of 300 - 450 mg/day (in 2 
divided doses). Because of its shorter titration period and potentially 
efficacious starting dosage, pregabalin may provide analgesia more 
quickly than gabapentin.27,68 Thus, pregabalin has pharmacokinetic 
advantages compared to gabapentin. 
The IASP NeuPSIG guidelines16 acknowledge the additional efficacy 
of gabapentin and pregabalin in sleep disorders, and pregabalin in 
anxiety disorders associated with pain. Although gabapentin and 
pregabalin have few drug interactions, both can produce dose-
dependent dizziness and sedation, which can be reduced by starting 
with lower dosages and titrating cautiously. It is also important to 
note that both these medications require dosage reduction in patients 
with renal insufficiency.69,70
3.6.3.2 SNRIs (duloxetine and venlafaxine)
SNRIs are considered a first-line treatment option by most of the 
international guidelines, including the NeuPSIG guidelines27 (grade 
A) and the EFNS guidelines26 (level A for DPN), thus highlighting 
the efficacy of SNRIs for management of NeuP. Although the French 
guidelines16 recommend SNRIs for second-line therapy because of the 
lack of marketing authorisation, duloxetine and venlafaxine have grade 
A recommendations for DPN and sensory polyneuropathy respectively. 
Danish pain experts17 state in their review that duloxetine and venlafaxine 
have a well-documented efficacy in painful polyneuropathy. 
Although both duloxetine and venlafaxine have been studied in 
peripheral NeuP, especially in painful DPN, more evidence of efficacy 
is available for duloxetine.28,30,34,71 Venlafaxine has shown efficacy in 
painful polyneuropathies of different origins.31,72 Both duloxetine and 
venlafaxine are approved for the treatment of major depression disorder 
(MDD) and generalised anxiety disorder (GAD)73,74 and hence are the 
treatment of choice in NeuP patients with these co-morbid conditions. 
Nausea, the most frequent side-effect with duloxetine, occurs less 
Table 2. 3L approach to differential diagnosis of NeuP59
Listen Locate Look 
Neuropathic pain Common descriptors: 
shooting, electric shock, burning, 
tingling, itching, numbness 
The painful region may not 
necessarily be the same as the 
site of injury. Pain occurs in 
the neurological territory of the 
affected structure (nerve, root, 
spinal cord, brain) 
Apply bedside sensory tests
Conduct aetiology-specific tests 
if appropriate 
Nociceptive pain Common descriptors: 
aching, throbbing, stiffness 
Painful region is typically 
localised  at the site of injury 
Physical manipulation causes 
pain at site of injury 
Modified from Haanpaa et al.59
Table 3. Bedside assessment of negative and positive sensory symptoms and signs in patients with NeuP
Signs and symptoms Bedside assessment
Negative symptoms and signs
Tactile hypoaesthesia/numbness Touch skin with a painter’s brush, cotton swab, or gauze
Hypoalgesia Single pin-prick with a safety pin or sharp stick (e.g. cocktail stick/toothpick)
Thermal hypoaesthesia Cold (10°C): calibrated metal roller or glass with water, acetone
Hot (40°C): calibrated metal roller or glass with water
Evoked pain
Mechanical allodynia (dynamic) Stroke skin with a painter’s brush, cotton swab, or gauze
Mechanical hyperalgesia (static) Firm pressure applied with the finger
Mechanical hyperalgesia (punctuate/pin-prick) Prick with a safety pin, sharp stick, or stiff von Frey hair
Temporal summation Prick with safety pin or sharp stick at intervals of <3 s for 30 s duration
Cold hyperalgesia (20°C) Calibrated metal roller, glass with water, acetone
Control: objects at skin temperature
Heat hyperalgesia (40°C) Calibrated metal roller, glass with water
Control: objects at skin temperature
Mechanical deep hyperalgesia (somatic) Apply manual light pressure at joints or muscles
Adapted from Baron et al.56
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frequently if treatment is initiated at 30 mg/day and titrated after one 
week to 60 mg/day.75 According to the IASP NeuPSIG guidelines,41 
duloxetine 60 mg once daily appears to be as efficacious as 60 mg twice 
daily and is associated with fewer side-effects in painful DPN.  
SNRIs in general and duloxetine in particular pose a minor to 
moderate hepatic risk; the use of duloxetine is contraindicated in 
patients with severe hepatic impairment.73 Elevated blood pressure and 
clinically significant electrocardiogram (ECG) changes are associated 
with patients treated with venlafaxine.74 Therefore, venlafaxine 
should be prescribed with caution in patients with cardiac disease 
and with regular BP monitoring. Venlafaxine should be tapered 
when treatment is being discontinued as a withdrawal syndrome 
Table 4a. Recommended first- and second-line agents for peripheral NeuP by international and national/regional guidelines
IASP, 201027 EFNS 201026
Latin 
America, 
200918 MER, 201021 FAR, 201122 CPS, 200719
French, 
201016
Danish, 
201017
First line Pregabalin 
Gabapentin 
SNRIs 
TCAs 
Topical 
lidocaine 
(localised 
peripheral 
NeuP)
Tramadol 
and opioids* 
Pregabalin
Gabapentin 
SNRIs (for 
DPN)
TCAs 
Topical 
lidocaine (for 
PHN)
TCAs
Topical 
lidocaine 
(localised 
peripheral 
NeuP)
Pregabalin 
Topical 
lidocaine 
TCAs 
Pregabalin 
Gabapentin 
Topical 
lidocaine 
TCAs
Pregabalin 
Gabapentin 
TCAs
Pregabalin 
Gabapentin 
SNRI† 
(duloxetine)
TCAs 
Tramadol 
(for mixed 
pain)
Topical 
lidocaine (for 
PHN with 
allodynia)
Pregabalin 
Gabapentin 
SNRIs
TCAs 
Topical 
lidocaine 
(PHN 
or focal 
neuropathy 
with 
allodynia)
Second line Opioids
Tramadol
For poly-
neuropathy: 
tramadol 
followed 
by strong 
opioids
For PHN: 
opioids and 
capsaicin 
Pregabalin 
Gabapentin 
Tramadol 
(for mixed 
pain)
SNRIs 
Opioids 
(tramadol, 
oxycodone or 
others)
SNRI 
(duloxetine)
SNRIs
Topical 
lidocaine 
TCA 
(maprotiline)
SNRI† 
(venlafaxine)
Opioids 
Tramadol
Tramadol
Opioids
Combination 
therapy
* For patients with acute NeuP, NeuP due to cancer, and episodic exacerbations of severe NeuP, as well as when titrating one of the first-line medications if prompt relief of pain is required.
† Venlafaxine is not proposed as first line given the absence of marketing authorisation in France.
IASP – International Association for Study of Pain; EFNS – European Federation of Neurological Societies; MER – Middle East Region; FAR – French-speaking Magreb region; CPS – Canadian 
Pain Society; SNRIs – serotonin-noradrenalin reuptake inhibitors; TCAs – tricyclic antidepressants; DPN - diabetic peripheral neuropathy; PHN – postherpetic neuralgia.
Table 4b. Recommended agents for specific peripheral NeuP aetiologies (painful DPN and PHN)
AAN, 2010 (for painful DPN)20 AAN, 2004 (for PHN)24
Level A/group 1* Pregabalin Pregabalin
Gabapentin
Lidocaine patch
Oxycodone or morphine sulphate, controlled 
release
TCAs
Level B/group 2† Gabapentin
Sodium valproate, SNRIs 
TCA (amitriptyline)
Opioids (dextromethorphan, morphine 
sulfate, tramadol, oxycodone) 
Capsaicin (topical)
Isosorbide dinitrate spray
Aspirin (cream/ointment)
Capsaicin (topical)
Methylprednisolone (intrathecal)
AAN – American Academy of Neurology; DPN - diabetic peripheral neuropathy; PHN – postherpetic neuralgia; SNRIs – serotonin-noradrenalin reuptake inhibitors; TCAs – tricyclic antide-
pressants
*Level A recommendation: established as effective, ineffective or harmful (or established as useful/predictive or not useful/ predictive) for the given condition in the specified population (level A 
rating requires at least two consistent class I studies) (in exceptional cases, one convincing class I study may suffice for an ‘A’ recommendation if: (i) all criteria are met; and (ii) the magnitude of 
effect is large (relative rate improved outcome >5 and the lower limit of the confidence interval is >2).
*Group 1. Medium to high efficacy, good strength of evidence, and low level of side-effects.
†Level B recommendation: probably effective for the given condition in the specified population (level B rating requires at least one class I study or two consistent class II studies.)
†Group 2. Lower evidence than those listed in group 1, or limited strength of evidence, or side-effect concerns.
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has been described.76 Antidepressants 
are generally associated with increased 
risk of suicide; hence patients should 
be closely monitored (refer to Table 
5 for additional considerations). 
An additional consideration, when 
using relatively high doses (120 mg 
duloxetine, 225 mg venlafaxine), is the 
risk of precipitating manic episodes in 
vulnerable individuals.
 
3.6.3.3 Low-dose TCAs (amitriptyline, 
imipramine, nortriptyline) 
Published international guidelines 
including the EFNS26 (level A evidence 
for DPN and PHN), IASP NeupSIG27 
(grade A), French guidelines (grade 
A scientific evidence in several 
aetiologies) as well as the systematic 
review by Danish experts17 have 
documented the efficacy of TCAs for 
treating a variety of types of NeuP. 
A Cochrane review34 that considered 
data from 17 studies validated the 
efficacy of TCAs in NeuP. 
TCAs are an attractive option 
mainly because they are inexpensive 
and have a convenient once-daily 
dosing. Although TCAs are approved 
to treat MDD, the analgesic effect is 
independent of the antidepressant 
effect, and occurs at a lower dose.27 
Therefore, low-dose TCAs are not the 
NeuP treatment of choice in patients 
with comorbid depression. Starting 
doses of amitriptyline should be low 
(10 - 25 mg/day), and titrated slowly 
until pain is adequately controlled or 
side-effects limit continued titration. 
It is important to take into account 
the potential for drug interactions, 
especially when amitriptyline is 
co-administered with drugs that 
inhibit CYP2D6 enzyme. TCAs are 
associated with cardiac toxicity and 
hence amitriptyline is contraindicated 
in patients who have ischaemic 
heart disease or an increased risk of 
sudden cardiac death.77,78 The MER 
guidelines21 recommend a screening 
ECG before beginning treatment with 
TCAs in patients over 40 years of age. 
Amitriptyline should be avoided in 
elderly patients. Please refer to Table 
5 for additional safety considerations.
3.6.3.4 Opioids (tramadol, morphine 
and methadone)
The IASP NeuPSIG guidelines27 
reviewed several high-quality RCTs that 
showed the efficacy of opioid analgesics 
including tramadol in patients with 
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different types of NeuP and recommend them as second-line agents 
(grade A), except in certain specific clinical situations in which first-
line use could be considered. The EFNS guidelines26 recommend 
opioids as second- or third-line agents with level A evidence for 
DPN and PHN. A systematic review by Danish pain experts17 also 
acknowledged the consistent efficacy of opioids in NeuP.
Tramadol is a weak µ-opioid agonist that inhibits the reuptake 
of noradrenalin and serotonin. It has been shown to reduce 
pain in DPN and sensory polyneuropathies; although it may 
be less efficacious than strong µ-agonists.79 The risk of abuse 
with tramadol appears considerably less compared with opioid 
analgesics.75 The EFNS guidelines26 cautions the use of tramadol 
in elderly patients because of risk of confusion and does not 
recommended tramadol with drugs acting on serotonin reuptake 
such as selective serotonin reuptake inhibitors (SSRIs). The 
French guidelines16 recommend tramadol for treatment of mixed 
pain (pain with nociceptive and neuropathic components) as it is 
effective in nociceptive pain.
Cochrane reviews have demonstrated the effectiveness of strong 
opioids (oxycodone, morphine, and methadone) in different types 
of NeuP, providing greater pain relief than placebo.38,80 In head-to-
head comparisons, opioids provided at least as much analgesia as 
TCAs and gabapentin.81,82 Despite strong evidence of efficacy, most 
of the international guidelines reserve opioid analgesics as second- or 
third-line agents mainly because of risk of long-term side-effects and 
possible opioid misuse and addiction. The IASP NeuPSIG guidelines 
estimate that the frequency of these problems associated with opioid 
analgesics ranges widely from less than 5% to as much as 50%. Hence, 
prior to initiating opioids, clinicians should take into account the risk 
factors for abuse, which include active or previous substance abuse 
and family history of substance abuse.75
3.6.4 Recommendations for peripheral NeuP
The panel reviewed the evidence and constructed a treatment algorithm 
(Fig. 3) to aid step-wise management of non-localised NeuP.
3.6.4.1 First-line treatment
Three classes of drugs are recommended for first-line monotherapy: 
α2δ-ligands (pregabalin or gabapentin), TCAs (low-dose amitriptyline 
or other TCA) and SNRIs (duloxetine or venlafaxine). Pregabalin is 
the preferred first-line option because of its simple pharmacokinetics 
and good tolerability. The choice of drug also depends on additional 
factors summarised in Table 5. 
Patients should be evaluated at 2 - 4 weeks after initiating therapy 
to determine response to treatment. If the response is good, the 
current treatment should be maintained, and if the response is 
sustained for 3 months, slow down-titration can be attempted. If 
symptoms return, treatment should be titrated back to an effective 
dose. If a partial response is seen at 2 - 4 weeks, consider increasing 
the dose of the current agent. If the response is poor, or the drug is 
not tolerated, move to second-line approaches.
3.6.4.2 Second-line therapy – combination
In case of partial response to first-line therapy, recommendations 
include either increasing the dose of the current drug or adding a drug 
from a different class. In case of complete failure to first-line therapy, 
the patient should be switched to a drug from a different class.
For combination treatment, pregabalin with either an SNRI or 
amitriptyline is recommended. It is important to note that although TCA 
and SNRI are different classes of antidepressant they target the same 
mechanism, so a combination of SNRI and TCA is not recommended.
Combination therapy may offer additional analgesic benefits 
and benefits on associated symptoms,83 but potential advantages 
must be weighed against the possibility of additive adverse effects, 
drug interactions, increased cost, and reduced adherence to a more 
complex treatment regimen.41 
3.6.4.3 Third-line treatment
If the patient does not respond to combination therapy or the switch 
strategy, tramadol is recommended (especially in NeuP with a 
nociceptive component) followed by strong opioids (e.g. morphine, 
oxycodone, hydromorphone), or a combination of first-line options 
with opioids. 
Evidence for these combinations is limited, but the combination 
of morphine and gabapentin seems to provide better pain relief 
than each drug given alone.82 In another study, a combination of 
gabapentin and an opioid was associated with significant pain relief 
and improved sleep, without an exacerbation of opioid-induced 
adverse events.84  
3.6.4.4 Follow-up
The tools and scales used for diagnosis may be useful for clinical 
monitoring (though not all are validated for this use) to establish a 
baseline and assess the patient’s response. Monitoring for potential 
drug interactions, adverse events, co-morbidities, need for dose 
titration, etc., should be part of the follow-up plan.
If a patient does not show a satisfactory therapeutic response, he/
she should be referred to a pain specialist centre. 
3.6.5 Aetiology-based recommendations
3.6.5.1 Polyneuropathy 
Painful DPN: The EFNS guidelines26 recommend the use of TCAs, 
gabapentin, pregabalin and SNRI (duloxetine, venlafaxine) as 
first-line treatment in painful polyneuropathy (notably related to 
diabetes), tramadol as second-line therapy and strong opioids as 
third-line agents.
Recommendations: The panel recommends use of pregabalin 
or gabapentin, low-dose amitriptyline (or other TCA), duloxetine 
or venlafaxine (SNRIs) for treatment of painful polyneuropathies, 
including painful DPN. If response to treatment is poor, patients 
should be switched to, or have added, a drug from a different class. 
Tramadol and opioids are recommended after failure of second-line 
or combination therapy. 
Painful HIV-SN: A recent systematic review of pharmacological 
treatment of HIV-associated neuropathy15 identified only 3 agents 
Fig. 3. Algorithm for the treatment of non-localised peripheral neuropathic 
pain.
Scientific Letter
322  May 2012, Vol. 102, No. 5  SAMJ
GUIDELINE
with good evidence of efficacy (v. placebo): smoked cannabis 
(1 - 8% δ-9-tetrahydrocannabinol), high-dose topical capsaicin 
(8%), and recombinant human nerve growth factor (rhNGF). 
Lamotrigine had limited efficacy in one trial, demonstrating 
superiority over placebo in a secondary endpoint and only in 
patients exposed to neurotoxic ARVs.15 Drugs that are generally 
effective for peripheral neuropathic pain of other aetiologies 
(amitriptyline, pregabalin, and gabapentin) have been studied 
but with no evidence of efficacy, and there have been no RCTs of 
SNRIs in HIV-associated neuropathy. 
Recommendations: Because of the lack of evidence for treatment of 
HIV-SN, the panel recommends following the framework outlined for 
other polyneuropathies and the step-wise management as illustrated 
in Fig 3. In addition, if the onset of the neuropathy is associated with 
starting antiretroviral therapy (even if it is a tenofovir-based regimen), 
then an alternative regimen should be considered, where possible. 
3.6.5.2 Postherpetic neuralgia 
Systematic reviews including a review by the AAN concur that 
gabapentin, pregabalin, TCAs, lidocaine patches and strong opioids 
have strong evidence of efficacy in PHN.24,29,34 Opioids have similar 
or slightly better efficacy compared with TCA but are associated with 
more frequent discontinuation because of side-effects.26,29 Because of 
the lack of RCTs, the efficacy of SNRIs duloxetine and venlafaxine for 
the treatment of PHN is not known. 
The EFNS guidelines26 state that although topical lidocaine patches 
are effective for the treatment of PHN with brush-induced allodynia, 
the level of evidence is lower compared with systemic agents.85 Topical 
capsaicin has also reported modest benefits in patients with PHN.29 
Recommendations: The panel recommends pregabalin, gabapentin 
or amitriptyline for first-line treatment of PHN, and to combine 
drugs from different classes as a second-line approach. Opioids 
(tramadol, then stronger opioids) should be reserved for third-line 
treatment.
As a topical lidocaine patch is not available in South Africa, 
the panel could not recommend its use despite strong supporting 
evidence. Topical capsaicin is also not available in South Africa, so 
it cannot be recommended. The panel suggests that the regulatory 
authorities in South Africa consider approval of these agents for use 
in neuropathic pain.
3.6.5.3 Trigeminal neuralgia (TN)
The AAN-EFNS guidelines for TN23 recommend carbamazepine (200 
-1 200 mg/day) as the drug of choice in classic TN because of its robust 
treatment response; however, its efficacy may be compromised by 
poor tolerability and pharmacokinetic interactions.23,37 Oxcarbazepine 
has shown similar efficacy to carbamazepine for controlling pain in 
TN,23,26 but with fewer drug-drug interactions. The AAN-EFNS 
guidelines also comment on the lack of evidence for treatment of TN 
following failure of first-line therapy and acknowledge some evidence 
supporting add-on therapy with lamotrigine or a switch to baclofen, 
but recent Cochrane reviews conclude that there is insufficient 
evidence to recommend them in TN.36,39
Recommendations: The panel recommends the use of 
carbamazepine and oxcarbazepine for the treatment of TN.
3.6.6 Central NeuP (CP) 
Relatively few RCTs have been conducted in patients with CP, but 
results and clinical experience suggest that such conditions may be 
relatively more refractory to treatment than peripheral NeuP.27 
The EFNS guidelines,26 IASP NeuPSIG group recommendations,27 
and a systematic review by Danish pain experts17 assessed the 
available data and agreed that the use of pregabalin, gabapentin, and 
TCAs (specifically amitriptyline) is best supported for CP states, 
specifically spinal cord injury (SCI) and poststroke pain. The EFNS 
guidelines26 recommend these three agents as first-line options for 
CP, with tramadol or stronger opioids as second-line. Cannabinoids 
are suggested in multiple sclerosis (MS) if other treatments fail,26,27 
although poor availability and concerns about risk of abuse and 
precipitation of psychosis limit use. There is some mixed evidence for 
lamotrigine in SCI and post-stroke pain.26, 27
A systematic review of evidence by Danish pain experts did not 
include any RCTs with SNRIs in CP.17 A recent RCT which evaluated 
the effects of duloxetine on pain relief concluded that there is 
insufficient evidence for the efficacy of duloxetine in treatment of CP.86
Recommendations: Based on the scientific evidence and added 
benefit in treating comorbidities (depression, insomnia, anxiety), 
the panel recommends using pregabalin or amitriptyline for first-
line treatment of CP (Fig. 4). As a result of the consistent clinical 
experience, fewer contraindications and better risk/benefit ratio 
compared with TCAs, the panel agrees that pregabalin should be 
the preferred option. Treatment trials should be approached as for 
peripheral NeuP; switching to other first-line agent or combining 
drugs if treatment fails. Tramadol should be considered next, 
followed by stronger opioids. As cannabinoids are not available in 
South Africa they cannot be recommended. 
3.7 Non-pharmacological treatments
3.7.1 Companion treatments 
A recent review of the evidence supporting the potential 
complementary role of psychosocial treatments of patients 
with chronic pain suggest that a combination of psychological, 
pharmacological and physical therapies, tailored to the needs of 
the individual patient, may be the best approach.87 Transcutaneous 
electrical nerve stimulation (TENS) is widely used for NeuP and 
nociceptive pain, and while it lacks robust efficacy data,88 it is 
recommended by EFNS Task Force89 as a preliminary or as an 
adjunct to analgesic therapy as it is inexpensive, non-invasive, safe, 
and can be self-administered. A review of non-pharmacological 
treatment approaches by Guastella et al.,90 indicate TENS in focal 
neuropathic pain when upstream stimulation is possible for a 
superficial sensitive nerve trunk. There are no good data supporting 
the use of acupuncture in NeuP.
Recommendation: The panel recommends the use of 
psychotherapy, particularly cognitive behavioural therapy, and 
TENS alongside appropriate physiotherapy and pharmacological 
Fig. 4. Recommendations for management of central neuropathic pain.
Scientific Letter
323  May 2012, Vol. 102, No. 5  SAMJ
GUIDELINE
treatment, for the management of NeuP. Comprehensive patient 
education can also help improve treatment outcomes. 
3.7.2 Stimulatory treatments and surgical management (non-
invasive and invasive) 
Non-invasive electrical stimulation of the brain, using a variety of 
methods, has been studied in some chronic pain conditions with 
very limited evidence of efficacy.91
Spinal cord stimulation, via electrodes implanted into the spinal 
cord, has limited evidence of efficacy in failed back surgery 
syndrome and complex regional pain syndrome type I,90 the 
EFNS Task Force identified level B evidence of efficacy in several 
systematic reviews, as well as primary studies for spinal cord 
stimulation in these two conditions.89 Guastella et al.90 suggest the 
use of spinal cord stimulation in segmental mononeuropathies 
refractory to drug treatment. 
Dorsal root entry zone lesioning (DREZotomy) involves destruct- 
tion of nociceptive fibres and the dorsal root entry zones in an aim 
to destroy the neurones that sustain the painful state. Guastella et 
al.90 suggest its use in refractory pain due to plexus avulsion.
Recommendations: The panel did not discuss these non-
pharmacological treatment approaches extensively, but recommends 
spinal cord stimulation in cases of pain that cannot be managed by 
pharmacological and companion treatments. The panel does not 
recommend DREZotomy for management of any NeuP, because of 
limited evidence and risk of worsening of NeuP after this invasive 
procedure.
4. Discussion
The management of NeuP is challenging, and even when NeuP is 
diagnosed and treated according to the best evidence available, not 
all patients can achieve a satisfactory response. This article provides 
recommendations for the management of NeuP in South Africa, with 
the aim of raising awareness of NeuP and improving its diagnosis and 
treatment in this country. These recommendations apply published, 
international, evidence-based guidelines for NeuP management to 
the South African setting. 
NeuP is widely underdiagnosed in South Africa, and the panel 
recommends the use of simple questionnaires, such as DN4, to identify 
NeuP. A raised awareness of common signs and symptoms of NeuP, 
and of the descriptors used by patients, will also help clinicians to better 
identify those patients who have neuropathic aspects to their pain.
For management of peripheral NeuP, the α2δ-ligands pregabalin and 
gabapentin, low-dose TCAs, and the SNRIs duloxetine and venlafaxine 
are recommended as first-line options. Pregabalin is the preferred 
option, based on tolerability and pharmacokinetics. Opioids should be 
reserved for later use, and only after switching to another monotherapy 
or combination therapy with multiple first-line agents fails. 
For painful DPN, recommendations are as for peripheral NeuP 
in general; for PHN, first-line recommendations are pregabalin 
(preferred), gabapentin and low-dose amitriptyline; and for TN, 
oxcarbazepine (preferred) and carbamazepine. Some agents with 
good evidence, recommended in guidelines from other regions, 
are not available in South Africa. The panel requests that the South 
African regulatory authorities evaluate the evidence for the lidocaine 
patch and topical capsaicin in localised peripheral NeuP and consider 
approval of these agents in South Africa. 
Based on current international recommendations, the committee 
cannot recommend specific therapy for the management of HIV-
associated neuropathy. Currently these patients should be managed 
following the same recommendations used for the management of 
peripheral neuropathic pain.
Evidence in CP is less consistent than for peripheral NeuP, 
but first-line recommendations are pregabalin (preferred) and 
amitriptyline. 
Companion therapies, such as cognitive-behavioural therapy 
(and other psychotherapy) and physical therapy are recommended 
to accompany pharmacological management. Invasive options like 
DREzotomy are not currently recommended. 
The recommendations presented here have several limitations. 
Evidence is still lacking for the relative efficacy of agents for NeuP, 
as there are very few head-to-head trials. There are also limited data 
available for pain due to specific aetiologies other than painful DPN, 
PHN, and TN. In particular, the paucity of evidence for treatment of 
painful HIV-SN makes it impossible to provide an evidence-based 
recommendation for this problem that is so common in South 
Africa. This must be a priority area of future research. In addition, 
because there are few placebo-controlled RCTs in South African 
populations, the recommendations given here have to assume that 
results in other populations can be extrapolated to the various 
ethnic groups represented in South Africa. 
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